Influence of DTPA Treatment on Internal Dose Estimates.
In case of internal contamination with plutonium materials, a treatment with diethylene triamine pentaacetic acid (DTPA) can be administered in order to reduce plutonium body burden and consequently avoid some radiation dose. DTPA intravenous injections or inhalation can start almost immediately after intake, in parallel with urinary and fecal bioassay sampling for dosimetric follow-up. However, urine and feces excretion will be significantly enhanced by the DTPA treatment. As internal dose is calculated from bioassay results, the DTPA effect on excretion has to be taken into account. A common method to correct bioassay data is to divide it by a factor representing the excretion enhancement under DTPA treatment by intravenous injection. Its value may be based on a nominal reference or observed after a break in the treatment. The aim of this study was to estimate the influence of this factor on internal dose by comparing the dose estimated using default or upper and lower values of the enhancement factor for 11 contamination cases. The observed upper and lower values of the enhancement factor were 18.7 and 63.0 for plutonium and 24.9 and 28.8 for americium. For americium, a default factor of 25 is proposed. This work demonstrates that the use of a default DTPA enhancement factor allows the determination of the magnitude of the contamination because dose estimated could vary by a factor of 2 depending on the value of the individual DTPA enhancement factor. In case of significant intake, an individual enhancement factor should be determined to obtain a more reliable dose assessment.
*Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Department of Internal Dosimetry, IRSN/PRP-HOM/SDI/LEDI, BP 17, F-92262 Fontenay-aux-Roses Cedex, France; †AREVA, Bioassay Laboratory, LBM, F-50440 Beaumont-Hague, France; ‡AREVA, Mining BG HSE-RP Department, F-92084 Courbevoie, France.
Estelle
E
Davesne
Eric
E
Blanchardon
Bernadette
B
Peleau
Philippe
P
Correze
Sandra
S
Bohand
Didier
D
Franck
D000576:Americium / Q000493:pharmacokinetics / Q000652:urine*; D001822:Body Burden; D002614:Chelating Agents / Q000008:administration & dosage; D003666:Decontamination / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D005243:Feces / Q000737:chemistry; D006801:Humans; D004369:Pentetic Acid / Q000008:administration & dosage*; D011005:Plutonium / Q000493:pharmacokinetics / Q000652:urine*; D011829:Radiation Dosage; D000069079:Radiation Exposure / Q000032:analysis*; D011837:Radiation-Protective Agents / Q000008:administration & dosage*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D002614:Chelating Agents; D011837:Radiation-Protective Agents; D011005:Plutonium; D004369:Pentetic Acid; D000576:Americium